Aprea Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $3.72 |
| Prev. Close | $3.75 |
| EPS | 12.31 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $13.48M |
| PE Ratio | 0.29 |
| low | high | |
|---|---|---|
| Day Range | 3.60 | 3.93 |
| 52 Week Range | 2.78 | 12.00 |
| Ratios | |
|---|---|
| P/B Ratio | 0.68 |
| Revenue | - |
| Operating M. % | -1,102.72% |
| Earnings | -$13.28M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -51.87% |
| EPS | 12.31 |
Score Breakdown
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| APRE | Market | |
|---|---|---|
| Value | 83 | 42 |
| Quality | 39 | 46 |
| Ownership | 13 | 39 |
| Growth | 77 | 44 |
| Dividends | - | 32 |
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Aprea Therapeutics Inc (APRE)
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Oren Gilad Ph.D.
- Headquarters
- Doylestown
- Employees
- 9
Keep an eye on Aprea Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.